Olink Holding AB (publ)
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jon Heimer
- Full Time Employees
- 707
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- Uppsala Science Park Uppsala Sweden 751 83
- IPO Date
- Mar 26, 2021
- CIK
- 0001835539
- Website
- olink.com
- Similar Companies
- Business
- Olink Holding AB (publ) develops and commercializes proteomics solutions for academic, government, biopharmaceutical, biotechnology and service provider institutions focused on life science research; its core products and services include Olink Explore HT for measuring over 5,400 proteins with proven specificity in areas such as cardiovascular, metabolic, oncology, neurology and inflammation diseases; Olink Target 96 and Target 48 panels offering up to 92 and 45 targeted biomarkers respectively across 15 panels and specialized offerings for immune surveillance, cytokines and neurodegeneration processes; Olink Flex for low-plex custom studies combining up to 30 biomarkers from a library of approximately 200 pre-validated assays; Olink Reveal providing NGS-based proteomics; Olink Signature Q100 as a qPCR readout platform; Olink Analysis services encompassing study design, consultation, sample preparation, assay execution, data processing, quality control and bioinformatics; Olink normalized protein expression (NPX) Manager software for data import, analysis, visualization and statistical modeling; and Olink Insight as a cloud platform for proteomics data visualization and community collaboration. The company operates globally through direct sales forces in the Americas, Europe, the Middle East, Africa and Asia Pacific, targeting biopharma companies, clinical and academic institutions to advance biomarker discovery, precision medicine and drug development across multiple disease areas with minimal sample volumes of 1-2 µL from plasma, serum and other matrices. Founded in 2004 and headquartered in Uppsala, Sweden at Uppsala Science Park, Olink Holding AB (publ) -- formerly Knilo HoldCo AB until its January 2021 name change -- functions as a subsidiary of Thermo Fisher Scientific Inc. following the latter's completion of its $3.1 billion acquisition in July 2024, which integrates Olink into Thermo Fisher's Life Sciences Solutions segment to expand proteomics capabilities complementary to mass spectrometry offerings; recent developments include the launch of the Olink Target 48 Neurodegeneration panel to enhance research in neurodegenerative diseases and promotional bundles combining neurodegeneration assays with cytokine or immune surveillance panels, alongside contributions to landmark UK Biobank proteogenomics studies revealing novel disease genes and therapeutic targets.
Olink® Reveal Seamlessly Connects Genomics and Proteomics, Empowering Researchers to Uncover the Dynamic Mechanisms Underlying Biology
Notice to attend the Extra General Meeting of Olink Holding AB (publ)
Olink's (OLK) Acquisition by Thermo Fisher Gets UK CMA Nod
Olink Announces Receipt of CMA Clearance for Proposed Acquisition by Thermo Fisher
UK's competition regulator clears $3.1 bln Thermo Fisher Scientific-Olink deal
Report from the Extra General Meeting of Olink Holding AB (publ) on 5 July 2024
Olink® Introduces Global Network of Certified Service Providers to Accelerate Protein Biomarker Discovery
Notice to attend the Extra General Meeting of Olink Holding AB (publ)
Olink® Target 48 Immune Surveillance Panel – The Next Frontier in Immune Biomarker Profiling with Absolute Confidence
Lab Instrument Industry Update - New Commercial Entrants
Olink Holding AB (publ) Sponsored ADR (OLK) Reports Q1 Loss, Lags Revenue Estimates
Olink reports first quarter 2024 financial results
UK's CMA kicks off probe into Thermo Fisher-Olink deal
Sampled Named One of the First Olink® Certified Service Providers
Report from the Annual General Meeting of Olink Holding AB (publ) on 19 April 2024
Olink reports fourth quarter and full year 2023 financial results
Notice to attend the Annual General Meeting of Olink Holding AB (publ)
Olink announces change of date for Annual General Meeting
Forget Quantum-Si Stock, Olink Acquirer Thermo Fisher Is a Better Long-Term Investment
Olink reports third quarter 2023 financial results